Multi-Attribute Methods for Biopharmaceutical Analysis

Significance of the Topic

Multi-Attribute Method (MAM) analysis by LC-MS enables direct, attribute-specific measurement of biotherapeutic variants that underlie efficacy, safety, stability and manufacturability. This contrasts with legacy chromatographic or electrophoretic assays that infer product quality indirectly and can miss low-abundance variants. MAM promises streamlined workflows, improved sensitivity, and broader dynamic range, supporting Quality by Design and accelerated decision-making across development, manufacturing and QC.

Objectives and Article Overview

This e-Book assembles three expert perspectives on advancing MAM in the biopharmaceutical industry:

• Transitioning LC-MS from characterization to routine multi-attribute monitoring in development
• Deploying MAM workflows for process science, manufacturing and quality control
• Avoiding common pitfalls in MAM assay development, validation and deployment

Each article describes the capabilities, adoption challenges and pathways to integrate MAM across the molecule life cycle.

Methodology and Instrumentation

MAM workflows are implemented at three structural levels:

• Peptide-level mapping: enzymatic digestion, separation and MS detection of tryptic peptides
• Subunit-level analysis: enzymatic fragmentation or partial reduction of monoclonal antibodies
• Intact protein analysis: direct measurement of molecular mass without digestion

Key instrumentation and automation platforms include:

• ACQUITY Premier UPLC System with MaxPeak High Performance Surfaces chemistry for robust, metal-free separations
• BioAccord LC-MS System and ACQUITY QDa mass detector for simplified, fit-for-purpose MS operation
• Xevo G3 QTof for high-resolution MS/MS characterization of unknown peaks
• Andrew+ pipetting robot for automated sample digestion and cleanup
• waters_connect and Empower CDS informatics for integrated data acquisition, processing, review and reporting under 21 CFR 11 compliance

Main Results and Discussion

• Demonstrated transition of LC-MS MAM from high-expertise characterization to routine attribute monitoring in clone screening, stability and formulation studies
• Showcased deployment of robust, validatable peptide MAM assays for in-process monitoring and QC release in regulated environments using QDa and BioAccord platforms
• Identified critical factors in MAM robustness: automated sample prep, inert UPLC flow paths, consistent column chemistries and proactive system diagnostics
• Described informatics strategies to automate new peak detection with advanced alignment, quality filters and data-independent MS/MS acquisition

Benefits and Practical Applications

• Consolidation of multiple single-attribute assays into a single MAM workflow reduces testing burden and risk of out-of-spec results
• Direct quantitation of site-specific modifications (deamidation, oxidation, glycosylation) enhances process understanding and control
• New peak detection extends MAM beyond target attributes to monitor unknown variants and impurities, supporting product consistency and patient safety
• Automated informatics streamlines data handling, minimizes manual intervention and ensures regulatory compliance

Future Trends and Potential Applications

• Continued automation of sample prep, LC-MS setup and data processing to expand MAM access to non-expert users
• Integration of artificial intelligence and machine learning to improve new peak detection, fragment annotation and trend analysis
• Adoption of MAM as a primary purity assay in regulatory filings, supported by cross-laboratory performance data
• Closed-loop process control using real-time MAM feedback in biomanufacturing
• Broader use of MAM for next-generation modalities (bispecifics, cell and gene therapies)

Conclusion

MAM analysis is moving from proof-of-principle to mainstream application, empowering biopharmaceutical developers and manufacturers with deeper insight, greater efficiency and more robust quality control. End-to-end solutions—spanning automated sample preparation, inert UPLC separations, intuitive MS systems and compliant informatics—enable scalable MAM deployments from early development through commercial QC. Continued innovation and partnership with experienced vendors will drive wider industry adoption and regulatory acceptance of attribute-based LC-MS analysis.

References

• Rogstad S et al. A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications. J Am Soc Mass Spectrom. 2017;28(5):786–794.
• Rogstad S et al. Multi-Attribute Method for Quality Control of Therapeutic Proteins. Anal Chem. 2019;91(22):14170–14177.
• Mouchahoir T et al. New Peak Detection Performance Metrics from the MAM Consortium Interlaboratory Study. J Am Soc Mass Spectrom. 2021;32(4):913–928.
• Mouchahoir T et al. Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study. J Am Soc Mass Spectrom. 2022;33(9):1659–1677.